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ABSTRACT
Objective: The purpose of this study was to develop an in situ ocular gel of ofloxacin which aimed to prolong corneal residence time while controlling 
drug release.
Method: In situ gelling solutions were prepared from Poloxamer 407, a temperature-sensitive gelling polymer and to which, mucoadhesive polymers 
such as hydroxypropyl methyl cellulose 15 cps and polyvinyl alcohol (PVA) were included to provide corneal adhesion. Drug incorporated gels were 
prepared and evaluated for their appearance, pH, gelation temperature, and in vitro drug release studies.
Results: Incorporation of the drug into the formulation increased the gelation temperature while the addition of mucoadhesive polymers decreased 
the gelation temperature. Increasing the concentration of bio-adhesive polymers retarded the release of ofloxacin from the poloxamer solutions and 
drug release was sustained over a period of 9 h. PVA had no significant effect on the gelation temperature and could not sustain the drug release for a 
longer duration. The in vitro release profiles of the drug from all the formulations could be best expressed by Higuchi’s equation which indicated that 
gels followed matrix diffusion process and drug release from gel formulations followed first-order process.
Conclusion: The results showed that the developed system would be promising in the treatment of ocular infections with the combined advantages 
of ease of administration, the accuracy of dosing, increased bioavailability, and prolonged retention time.
Keywords: Ofloxacin, Poloxamer 407, Gelation temperature, Muco-adhesive polymers.
INTRODUCTION
When eye drops are administered, the drug dose instilled undergoes 
drainage immediately upon instillation, i.e., within 5 min which is 
typical of ophthalmic solutions. Therefore to achieve the desired 
therapeutic effect, frequent instillation of solutions is required. Due 
to short precorneal residence time, ophthalmic bioavailability of only 
1%–10% is achieved. Systemic absorption of the drug drained through 
the nasolacrimal duct may result in some undesirable side effects. To 
overcome these problems and to extend the ocular residence time of 
medications for topical application to the eye, ophthalmic in situ gels have 
been investigated. In situ gel formation occurs due to one or combination 
of different stimuli such as pH change, temperature modulation, and 
solvent exchange. Smart polymeric systems represent promising means 
of delivering the drugs. Once administered these polymers undergo 
sol-gel transition. These biodegradable polymers have a wide range of 
clinical applications. Various natural and synthetic polymers are used 
for the development of in situ drug delivery systems [1].
The poloxamers or pluronics are biodegradable, nonionic triblock 
copolymers of ethylene oxide and propylene oxide capable of forming 
thermo-reversible gels. Pluronic F 68 and Pluronic F 127 have been 
approved by the Food and Drug Administration for use in the formulation 
of oral solutions, suspensions, topicals, inhalations, and nasal dosage 
forms [2]. They form sols at room temperature and undergo sol-to-gel 
transition at body temperature. In our investigations, we have used 
Pluronic F 127, also known as Poloxamer 407, the solutions of which 
gel at temperatures above 25°C [3]. Moreover, the aqueous solutions of 
this polymer can be easily sterilized by filtration.
The most common route of ocular drug delivery is topical delivery into 
the cul-de-sac of the eye [4]. The unique anatomy and physiology of the 
eye offer many challenges to develop effective ophthalmic drug delivery 
systems.
Ofloxacin is a synthetic fluoroquinolone agent widely used in the 
treatment of ocular conjunctivitis and other ocular disorders. 
Conventional eye drops of ofloxacin is a 0.3% solution of the drug used 
in a dose of 1–2 drops every 2–4 h in the control of conjunctivitis and 
for symptomatic relief of pain and inflammation [5].
In the present study, an attempt was made to develop an in situ 
ocular gelling system of ofloxacin which combines the advantages of 
conventional eye drops in terms of convenience of administration and 
dose accuracy and those of ophthalmic inserts in terms of prolonged 
residence time, extended and more efficient drug effects and decreased 
frequency of administration leading to better patient compliance.
MATERIALS AND METHODS
Materials
Ofloxacin was received as a gift sample from Sanofi Aventis Goa. 
Pluronic F 127 or Poloxamer 407, hydroxypropyl methylcellulose 
(HPMC) 15 cps and polyvinyl alcohol (PVA) were procured from Yarrow 
Chem Products, Mumbai. All the other chemicals used were of analytical 
grade.
Methods
Various compositions of drug-free in situ gelling solutions were prepared 
using Poloxamer, HPMC, and PVA in various ratios. The resulting 
polymer compositions were evaluated for physical characteristics such 
as appearance, pH, gelation temperature, and gelling capacity. The 
results of these studies were used to select the optimal compositions 
which were then incorporated with the drug [6].
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Preparation of drug incorporated gelling solutions
The gel-forming solutions were prepared by the cold method as used 
for the drug-free solutions. Poloxamer was added to half the quantity of 
distilled water with continuous agitation, and this polymer base was left 
at 4°C for 24 h to dissolve until a clear solution was obtained. Required 
percentage of benzalkonium chloride was added as preservative to this 
polymer base. Mucoadhesive polymers such as PVA and HPMC were 
dissolved in distilled water which was then added to the poloxamer 
solution and diluted up to 25 ml. The drug was separately dissolved 
in buffer and was added to the polymer solution and adjusted to the 
required volume to form a clear solution [7].
Evaluation of drug incorporated in situ gelling solutions
Appearance and pH
The developed formulations were visually inspected for clarity in sol 
and gel form.
The pH of the formulations was determined using the pen pH meter, by 
bringing the electrode in contact with the surface of the formulations [8.9].
Viscosity measurement
The viscosity was measured using a Brookfield viscometer and the 
angular velocity increased gradually from 2 to 50 rpm. The studies were 
performed using spindle no. 96 for gels at physiological temperature 
(37°C) and for sols at normal room temperature (28°C) [10]. The 
viscosity of measured formulations is given in Tables 1 and 2.
Measurement of gelation temperature
About 10 ml of the formulation was transferred to a 50 ml beaker with 
a magnetic bead and placed on a magnetic stirrer with thermostatically 
controlled heater. The temperature of the stirrer was increased in 
increments of 1°C and the temperature of the formulation was recorded 
using a thermometer. The rotation of bead gradually slowed down as 
the viscosity increased. The temperature at which the magnetic bead 
stopped rotating was taken as gelation temperature [11].
Gelling capacity
The gelling capacity was determined by placing a drop of the system in a 
vial containing 2 ml of simulated tear fluid (phosphate buffer of pH 7.4) 
freshly prepared and equilibrated at 37°C and visually assessing the gel 
formation and noting the time for gelation and the time taken for the 







Each formulation (8.3 ml) was taken in a 100 ml volumetric flask 
diluted with Phosphate buffer of pH 7.4 and shaken to dissolve the drug. 
The solution was filtered through Whatman filter paper and 1 ml of the 
filtered solution was taken and further diluted to 10 ml with artificial 
tear fluid. Drug content was estimated using an UV spectrophotometer 
by measuring the absorbance of the above solution at 288 nm. Results 
are given in Table 3.
In vitro diffusion studies
In vitro drug release studies were carried out in Franz–Diffusion (FD) 
cell using cellophane membrane as diffusion membrane and Phosphate 
buffer (pH: 7.4) as medium. The cellophane membrane (previously 
soaked overnight in the receptor medium) was tied at one end of the FD 
cell. One ml of artificial tear fluid was added to the donor compartment 
and 1 mL of the gel was spread uniformly on a cellophane membrane, 
which was in contact with the receptor medium. The receptor medium 
was stirred continuously at 20 rpm to simulate sink conditions. The 
whole assembly was placed on a magnetic stirrer and maintained at 36 
± 1°C to mimic physiological condition at which formulation remains 
in gel form. Aliquots of medium were withdrawn at appropriate time 
intervals, and equal volumes of fresh media were added to replace the 
withdrawn samples [13]. Withdrawn samples were filtered, diluted, 
and estimated by ultraviolet (UV) double beam spectrophotometer (UV 
Spectrophotometer- JASCO) at 288 nm.
Kinetic analysis of drug release data
The higher values of regression coefficient for the first-order equation 
indicated that percentage drug release from gel formulations probably 
followed first-order kinetics. Since it is a gel diffusion process, therefore 
to understand the mechanism of drug release the drug release data was 
also fitted to Higuchi’s Matrix model [14].
In vitro antimicrobial studies
When antibiotics are included in the formulations, it is necessary to 
carry out studies for evaluation against selective microorganisms, 
the results obtained are compared with that of suitable standards. 
For the studies, the medium used is the nutrient agar of pH7.4. After 
sterilization, the medium was kept aside at room temperature. The 
medium was poured into a sterilized petri dish to give a depth of 
3–4 mm and was ensured that the layer of medium is uniform in 
thickness. After solidification, a loop of diluted suspension culture 
(Staphyococcus aureus) in nutrient broth was added on to the surface 
of solidified agar and was spread uniformly with the help of L-shaped 
rod. After stabilization of culture, with the help of a sterile cork borer, 
cups of 6 mm diameter each were punched and scooped out from 
the petri dish. Gels of known concentration along with marketed and 
standard preparation were fed into the cup. The petri dish was then 
incubated for 24 hat 37°C. After incubation, the zone of inhibition 
(ZOI) was measured [15]. The entire operation was carried out 
in a laminar airflow unit. Each formulation solution was tested in 
triplicate. Both positive and negative controls were maintained 
throughout the study.
Table 1: Viscosity of (gel form) after thermo‑conversion in cps
Formulation code Viscosity at 2 rpm Viscosity at 5 rpm Viscosity at 10 rpm Viscosity at 20 rpm Viscosity at 50 rpm
OG1 3543 2389 1357 711.6 310.4
OG2 3645 2265 1368 728.5 315.6
OG3 3543 2285 1370 728 319.5
OG4 3621 2293 1387 719.2 321
Table  2: Viscosity of formulations (sol form) in cps
Formulation code Viscosity at 2 rpm Viscosity at 5 rpm Viscosity at 10 rpm Viscosity at 20 rpm Viscosity at 50 rpm
OG1 16.4 12.0 7.31 2.9 1.31
OG2 16.5 14.0 7.50 2.71 1.10
OG3 18.7 15.0 7.5 2.81 1.12
OG4 18.1 15.2 7.19 2.77 1.14
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RESULTS AND DISCUSSION
On the basis of results from the evaluation of the physical characteristics 
such as appearance, pH, gelation temperature and gelling capacity, the 
selected compositions were incorporated with the drug. The formulae 
for the optimal compositions are shown in Table 4. All the formulations 
developed had a clear appearance in the sol form when stored at room 
temperature not exceeding 30°C.
The formulations were in the pH range of 6.6–7.2 which is well within 
the range specified for ocular formulations and which is considered 
acceptable to avoid the risk of irritation on application to the eye. This 
pH range provides a better environment for mucoadhesion as well 
as longer retention of formulation in the ocular cavity mentioned in 
Table 3.
The prepared formulations had an acceptable gelling capacity. 
Formulations OG2 and OG4 showed an acceptable gelling capacity and 
retained as a gel for a longer period. The formulations OG1 and OG3 
had lesser gelling capacity due to lesser concentration of mucoadhesive 
polymers along with poloxamer.
Incorporation of PVP in different concentrations had no significant 
effect on the gelation temperature, but the incorporation of 
HPMC led to a gradual decrease in the gelation temperature with 
increasing concentrations of the polymer as shown in Table 3. 
The results showed that the maximum gelation temperature of 
the drug formulations did not exceed 32°C. We can safely assume 
that the formulations were gelled at body temperature of 37.5°C 
and the inclusion of drug and additives did not appreciably affect 
the gelation temperature. The percentage drug content of all the 
prepared formulations was found to be within a range of 96.74%–
94.67% as shown in Table 3.
The gels were less viscous in solution form when compared to the gel 
state. As the rpm increased the viscosity decreased proportionately as 
shown by results given in Tables 1 and 5.
In vitro drug diffusion studies demonstrated that all the four 
formulations showed sustained drug release for 9 h. The combination 
of the poloxamer with HPMC or PVA showed faster dissolution in 9 h 
compared to solutions containing poloxamer alone. The release of the 
drug was prolonged with increased concentration of poloxamer in 
the formulation. This is probably because the increased viscosity of 
the poloxamer only formulation resulted in slower diffusion of the drug 
from the gel [16]. Formulations containing HPMC were able to show 
the better release of the drug over a duration of 9 h due to the lower 
viscosity of their gels compared to formulations containing the only 
poloxamer or in combination with PVA which retard the drug release 
considerably.
All the formulations showed the initial burst effect that may be 
attributed to the solution form of the formulation at the initial phase 
of drug release, after which the formulation undergoes thermo-
conversion to form a gel and resulting in sustained release of the drug 
from the formulation. Thus the release of the drug could be modulated 
by adjusting the concentration of the polymers to obtain a sustained 
drug release profile for 9 h.
The maximum percentage of drug release was found to be 91.40% in 
9 h from formulation OG2. The in vitro drug release profiles from all the 
formulations are depicted in Fig. 1.
Kinetic analysis of drug release data show that the diffusion of drug 
from the formulation took place by first order kinetics since the 
values for regression coefficient (R2) were higher than for the zero-
order model. Since drug release is a gel diffusion process, therefore 
to understand the mechanism of release, the data was further fitted 
to Higuchi’s Matrix model [16]. The results of the kinetic analysis as 
shown in Table 5, further supported the presumption that drug release 
from the gel followed a matrix diffusion process.
Microbial studies were carried out by taking the pure drug as a standard 
and marketed solution (ofloxacin eye drops, 0.3% w/v) as reference. 
Among all the formulations, formulation OG1 showed a maximum ZOI 
of 24 mm which was the result of the slow and sustained diffusion of 
the drug from the formulation due to its greater viscosity. On the other 
hand, formulations OG2 and OG3 showed significantly smaller ZOI when 
compared to OG1, OG4, the standard (0.3% w/v ofloxacin solution) 
and the marketed formulation. The study revealed that ofloxacin was 
Fig. 1: In vitro drug release profile of ofloxacin from in situ gelling 
solutions
Fig. 2: Zone of inhibition of all the gel formulations, pure drug, 
and marketed formulation
Table 3: Results for pH, gelling temperature, gelling capacity and drug content of drug incorporated polymer solutions
Formulation code Appearance pH* Gelation temperature* Gelling capacity Drug content (%)*
OG1 Light yellow 6.9±0.4 27±0.4 ++ 96.74±0.23
OG2 Light yellow 7.15±0.05 32±0.7 +++ 95.17±0.45
OG3 Light yellow 7.2±0.15 27.5±0.7 ++ 95.76±0.34
OG4 Light yellow 6.9±0.3 28.5±0.1 +++ 94.67±0.32
*Mean and SD of n determinations; n=3. SD: Standard deviation
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effective even after formulation as an in situ gelling system as shown 
in Fig. 2.
CONCLUSION
Rapid elimination of the eye drops, administered often results in a 
short duration of the therapeutic effect which results in repeated 
administration. However the in situ gelling system may be a viable 
alternative to parenteral administration routes, thus improving patient 
compliance and may provide enhanced bioavailability compared with 
other delivery systems. The present work was taken up to use the 
solutions of the thermo-reversible polymer, Poloxamer 407 together, 
with mucoadhesive polymers such as PVA and HPMC to develop an 
in situ gelling system of ofloxacin which can be beneficial in overcoming 
the limitations of other administration routes.
The concentration of Poloxamer 407 chosen for the formulations had 
gelation below the temperature of the ocular cavity and was also, found 
to have a good gelling capacity. All the formulations showed higher 
amount of drug content, indicating that the method adopted for the 
formulation is suitable. The specific objectives were achieved for which 
further an extensive investigation is needed for the clinical usefulness 
of the developed in situ gels containing ofloxacin.
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Table 4: Composition of developed in situ gel systems
Ingredients (g) OG1 OG2 OG3 OG4
Ofloxacin 0.075 0.075 0.075 0.075
Poloxamer 4 4 3.75 4.25
HPMC 15 cps - 0.75 1.125 -
PVA (Hot) - - - 0.2
Sodium dihydrogen phosphate 0.281 0.281 0.281 0.281
Benzalkonium chloride (% w/v) 0.0025 0.0025 0.0025 0.0025
Phosphate buffer pH 7.4 q.s q.s q.s q.s
HPMC: Hydroxypropyl methyl cellulose, PVA: Polyvinyl alcohol, QS: Quantity Sufficient










OG1 0.8732 0.9317 0.9397
OG2 0.8764 0.9903 0.9591
OG3 0.8715 0.9911 0.9898
OG4 0.858 0.9869 0.9831
